Biopharmaceutical companies have played a key role in the restoration of the economy and the global market since the destructive COVID-19 pandemic. It is thanks to their efforts that vaccines can be distributed to more than seven billion people. Unfortunately, even though more than 900 million people have already been vaccinated as of June 2021, that number is still only 12 percent of the global population.
Companies like Samsung Biologics play a crucial role by supporting biopharmaceutical companies in expediting patient access to life-saving biologics through manufacturing and developing the highest quality biologics as promptly and safely as possible..
Commitment to Expansion
Samsung Biologics knows that in order to establish a global presence, one must have a strategic focus on growth and expansion. In a speech given at BIO Digital 2021, Samsung Biologics CEO John Rim said, “As most recently announced, we are fully committed to leveraging our experience in manufacturing technologies to support the aseptic fill and finish of Moderna’s mRNA-1273 vaccine with quality, speed, and efficiency to aid in the fight against this global crisis.”
Rim continued, “We will be also adding a dedicated production suite for mRNA bulk drug substance to our prevailing capacity by the first half of 2022, which will enable us to rapidly manufacture and supply future vaccines and treatments against multiple targets.”
A mRNA vaccine drug substance manufacturing suite will be added to the existing facility in Songdo, South Korea. The company promises to deliver end-to-end mRNA vaccine industrial services from wholesale drug substance to sterile fill/finish including classification & wrapping, as well as cold chain packing. These trappings will be ready nearby the start of 2022.
“We are continuously assessing numerous ways that we can increase and spread our current business selection to better help the market,” said John Rim, CEO of Samsung Biologics. “We are committed to helping our clients provide quality treatments and vaccines to all those in need around the world, especially in difficult times like this, and with this extended capability, we hope to support our partners in bringing novel mRNA vaccines and therapeutics to market at a faster pace.”
Plant 4 in Incheon, South Korea, is also on track for completion. Samsung Biologics will grasp a total of 620,000 liters of cell ethos capacity and continue to deliver end-to-end, start-to-finish facilities to its clients when the plant is finished.
Commitment to Operational Excellence
In June 2021, Samsung Biologics announced that it had received four global ISO certifications: ISO22301 (Business Continuity Management), ISO50001 (Energy Management), ISO45001 (Occupational Health and Safety Management), and ISO14001 (Effective Environmental Management) from the British Standards Institution (BSI).
“We are extremely proud to obtain four global ISO certifications during a time where a high degree sustainable management system is vital, especially in light of COVID-19, to stably operate and supply crucial biomedicines for patients,” Rim said of the four certifications. “Samsung Biologics is a leading CDMO committed to taking responsibility and consideration of ESG factors across all of our business areas, and we will continue to enhance our capabilities to meet the evolving needs of clients whilst ensuring the safety and security of not only our people but also of the environment to ultimately create a better future for humanity.”